Collaboration, License, and Other Agreements (Tables)

12 Months Ended

Dec. 31, 2023

Table Text Blocks

Schedule of revenue attributable to transactions from collaboration and license arrangements

	Year Ended December 31,
Collaborative Arrangements Revenue	2023		2022		2021
Linaclotide Collaboration and License Agreements:
AbbVie (North America)	$	433,242	$	401,498	$	403,085
AbbVie (Europe and other)		2,779		2,444		2,558
AstraZeneca (China, including Hong Kong and Macau)		430		635		743
Astellas (Japan)		1,799		2,001		2,232
Other Agreements:
Alnylam (GIVLAARI)		—		2,194		2,411
AKP (apraglutide)		2,009		—		—
Other		2,476		1,824		1,755
Total collaborative arrangements revenue	$	442,735	$	410,596	$	412,784
Sale of API
Linaclotide Agreements:
Astellas (Japan)	$	—	$	—	$	149
AstraZeneca (China, including Hong Kong and Macau)		—		—		597
Other		—		—		223
Total sale of API	$	—	$	—	$	969

AbbVie Plc

Table Text Blocks

Schedule of revenue attributable to transactions from collaboration and license arrangements

	Year Ended December 31,
	2023		2022		2021
Collaborative arrangements revenue related to sales of LINZESS in the U.S.	$	430,463	$	398,767	$	400,371
Royalty revenue		2,779		2,731		2,714
Total collaborative arrangements revenue	$	433,242	$	401,498	$	403,085